Silver

證據等級: L5

預測適應症: 1 個

SILVER: From Unknown Indication to Bone Paget Disease

One-Sentence Summary

SILVER (DrugBank ID: DB12965) has no recorded original indication, no marketed formulation, and no mechanism of action data available. The TxGNN model predicts a possible association with Bone Paget Disease, but this prediction appears to stem from a data artifact rather than genuine pharmacological evidence — the supporting “evidence” consists of histological silver-staining technique papers, not treatment studies.

Quick Overview

Item	Content
Original Indication	Not available — no original indications recorded
Predicted New Indication	Bone Paget Disease
TxGNN Prediction Score	99.67%
Evidence Level	L5
US Market Status	Not marketed (未上市)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for SILVER. No original indications are on record, and the drug has not been approved or marketed in any reviewed jurisdiction, so there is no established clinical use to anchor a mechanistic rationale.

Critically, a review of the underlying literature suggests this prediction is not mechanistically grounded. All five literature citations relate to “silver staining” or “silver impregnation” — laboratory histology techniques used to visualize bone tissue sections (e.g., osteoclast nucleolar organizer regions, osteoid quantification) in Paget’s disease research. None of these papers describe silver as a therapeutic agent. It is highly likely that the TxGNN knowledge graph conflated the entity “silver” (the drug) with “silver stain” (a laboratory technique term) that co-occurs frequently in Paget’s disease pathology literature, producing a high confidence score (99.67%) that does not reflect real pharmacological relevance.

The two clinical trials returned are similarly unrelated: one is a general rare-disease patient registry (not a drug intervention study), and the other concerns phosphate management in end-stage kidney disease with no mention of silver or silver compounds. Neither provides support for a silver–Paget’s disease treatment relationship.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01793168	N/A	Recruiting	20,000	Rare disease patient registry (CoRDS); not a drug intervention trial, no direct link to silver or Paget’s disease treatment
NCT03573089	N/A	Recruiting	3,600	Phosphate-lowering strategy trial in dialysis patients; no mention of silver or related compounds

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9836854	1998	Review/Basic Science	Bone	Silver-stained (AgNOR) nucleolar organizer regions in osteoclast nuclei of Paget’s disease — a staining technique, not a treatment study
3163726	1988	Case study	J Nucl Med	Gallium-67 (not silver) citrate localization in Paget’s disease osteoclasts
4111887	1972	Histology technique	Stain Technology	Silver staining method for quantifying osteoid in bone sections — methodology paper, not a treatment study
2420233	1985	Histology technique	Anat Anz	Silver impregnation method for bone tissue — methodology paper, not a treatment study
9227338	1997	Basic Science	J Pathol	Vitamin D receptor mRNA quantification technique; no direct relevance to silver

US Market Information

Currently no marketed authorizations available — SILVER has 0 recorded licenses and a “未上市” (not marketed) status.

Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or drug interaction data are currently available for SILVER.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction score is high, but the underlying evidence is not credible — the literature base consists entirely of histological “silver staining” technique papers rather than therapeutic studies, and no clinical trials meaningfully support silver as a treatment for Bone Paget Disease. Combined with the absence of original indication, MOA, and market approval data, this candidate does not meet the threshold to proceed.

To proceed, the following is needed:

Resolution of the entity-confusion issue in the knowledge graph (distinguish “silver” the drug from “silver stain” the laboratory technique)
TFDA label warnings/contraindications (currently blocking — DG001)
Mechanism of action data from DrugBank or equivalent source (DG002)
Identification of any genuine original indication(s) for SILVER
If re-evaluated, a fresh literature search specifically excluding histology/staining-methodology papers
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.